Drug Profile
TCN 032
Alternative Names: Anti-influenza monoclonal antibody - Theraclone Sciences; IgG monoclonal antibody - Theraclone Sciences; TCN-032Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Theraclone Sciences
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Influenza A virus M2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Influenza A virus infections
Highest Development Phases
- Phase II Influenza A virus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-infections(In volunteers) in USA (IV, Infusion)
- 03 Aug 2015 Phase II development is ongoing in United Kingdom, and phase I development is ongoing in USA
- 10 Sep 2013 TCN 032 is available for licensing in World (excluding Japan) - www.theraclone-sciences.com